-
1 Comment
NOXXON Pharma N.V is currently in a long term downtrend where the price is trading 24.2% below its 200 day moving average.
From a valuation standpoint, the stock is 26.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 200.6.
Based on the above factors, NOXXON Pharma N.V gets an overall score of 1/5.
| Exchange | PA |
|---|---|
| CurrencyCode | EUR |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 3M |
|---|---|
| PE Ratio | None |
| Target Price | 0.5 |
| Dividend Yield | 0.0% |
| Beta | 2.24 |
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALNOX.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
